Penumbra Inc (NYSE:PEN) insider James Robert Pray sold 5,333 shares of the business’s stock in a transaction that occurred on Monday, November 18th. The stock was sold at an average price of $167.53, for a total transaction of $893,437.49. Following the sale, the insider now directly owns 1,578 shares of the company’s stock, valued at $264,362.34. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

James Robert Pray also recently made the following trade(s):

  • On Tuesday, October 22nd, James Robert Pray sold 5,333 shares of Penumbra stock. The shares were sold at an average price of $150.06, for a total transaction of $800,269.98.
  • On Monday, September 16th, James Robert Pray sold 658 shares of Penumbra stock. The shares were sold at an average price of $150.00, for a total transaction of $98,700.00.
  • On Thursday, September 12th, James Robert Pray sold 50 shares of Penumbra stock. The stock was sold at an average price of $150.00, for a total transaction of $7,500.00.

Shares of PEN stock traded down $0.61 on Wednesday, reaching $168.16. The company had a trading volume of 467,600 shares, compared to its average volume of 453,987. The company has a current ratio of 5.24, a quick ratio of 3.61 and a debt-to-equity ratio of 0.10. The stock has a market cap of $5.82 billion, a PE ratio of 329.73, a PEG ratio of 9.45 and a beta of 0.73. The company has a 50-day moving average of $154.57 and a 200-day moving average of $152.68. Penumbra Inc has a 12 month low of $110.84 and a 12 month high of $185.70.

Penumbra (NYSE:PEN) last announced its quarterly earnings results on Thursday, November 7th. The company reported $0.25 earnings per share for the quarter, beating analysts’ consensus estimates of $0.18 by $0.07. Penumbra had a net margin of 8.69% and a return on equity of 7.23%. The business had revenue of $139.50 million for the quarter, compared to the consensus estimate of $133.98 million. During the same period last year, the company posted $0.17 EPS. Penumbra’s revenue for the quarter was up 24.8% on a year-over-year basis. Sell-side analysts anticipate that Penumbra Inc will post 0.95 earnings per share for the current year.

A number of large investors have recently modified their holdings of the business. Amundi Pioneer Asset Management Inc. boosted its position in shares of Penumbra by 5.7% during the first quarter. Amundi Pioneer Asset Management Inc. now owns 110,746 shares of the company’s stock worth $16,280,000 after purchasing an additional 5,935 shares in the last quarter. KAMES CAPITAL plc raised its stake in Penumbra by 22.8% during the 2nd quarter. KAMES CAPITAL plc now owns 14,675 shares of the company’s stock worth $2,345,000 after buying an additional 2,728 shares during the period. Campbell & CO Investment Adviser LLC raised its stake in Penumbra by 40.9% during the 2nd quarter. Campbell & CO Investment Adviser LLC now owns 3,651 shares of the company’s stock worth $584,000 after buying an additional 1,060 shares during the period. CENTRAL TRUST Co bought a new position in Penumbra during the second quarter worth about $171,000. Finally, Thoroughbred Financial Services LLC lifted its holdings in Penumbra by 16,171.3% during the second quarter. Thoroughbred Financial Services LLC now owns 1,247,360 shares of the company’s stock worth $124,736,000 after acquiring an additional 1,239,694 shares in the last quarter. 92.29% of the stock is owned by hedge funds and other institutional investors.

Several brokerages have commented on PEN. Royal Bank of Canada set a $174.00 target price on shares of Penumbra and gave the company a “buy” rating in a research report on Wednesday, August 7th. ValuEngine downgraded Penumbra from a “buy” rating to a “hold” rating in a research note on Thursday, August 1st. Zacks Investment Research lowered Penumbra from a “buy” rating to a “hold” rating in a research report on Tuesday, October 29th. Finally, Wells Fargo & Co lifted their price objective on Penumbra from $185.00 to $195.00 and gave the stock an “outperform” rating in a research note on Friday, November 8th. Two analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Penumbra has a consensus rating of “Buy” and a consensus target price of $174.50.

About Penumbra

Penumbra, Inc designs, develops, manufactures, and markets medical devices in the United States, Europe, Canada, Australia, Japan, and internationally. The company offers neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, DDC, and PX SLIM brands; aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the ACE and the 3D Revascularization Device brands.

Read More: How to invest using market indexes

Insider Buying and Selling by Quarter for Penumbra (NYSE:PEN)

Receive News & Ratings for Penumbra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Penumbra and related companies with MarketBeat.com's FREE daily email newsletter.